Advances in the pathogenesis and diagnosis of multiple myeloma

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma

(2014) M Affer et al.   LEUKEMIA

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

(2014) Niccolo Bolli et al.   Nature Communications

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013

(2013) Joseph R. Mikhael et al.   MAYO CLINIC PROCEEDINGS

Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma

(2012) B. A. Walker et al.   BLOOD

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma

(2012) P. L. Bergsagel et al.   BLOOD

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

(2012) M. Chesi et al.   BLOOD

Clonal competition with alternating dominance in multiple myeloma

(2012) J. J. Keats et al.   BLOOD

Molecular pathogenesis of multiple myeloma and its premalignant precursor

(2012) W. Michael Kuehl et al.   JOURNAL OF CLINICAL INVESTIGATION

Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival

(2012) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival

(2011) K. D. Boyd et al.   CLINICAL CANCER RESEARCH

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma

(2011) W-J Chng et al.   LEUKEMIA

MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites

(2011) Huadong Pei et al.   NATURE

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

(2010) T. Steinbrunn et al.   BLOOD

The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells

(2010) E. Martinez-Garcia et al.   BLOOD

Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study

(2010) Angela Dispenzieri et al.   LANCET

A monoclonal gammopathy precedes multiple myeloma in most patients

(2009) B. M. Weiss et al.   BLOOD

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

(2009) R Fonseca et al.   LEUKEMIA

AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies

(2008) Marta Chesi et al.   CANCER CELL